Chhabra Arvind
Department of Medicine, University of Connecticut Health Center (UCONN Health), Farmington, CT, United States.
Front Immunol. 2017 Aug 18;8:993. doi: 10.3389/fimmu.2017.00993. eCollection 2017.
Donor-specific induced pluripotent stem cells (iPSCs) offer opportunities for personalized cell replacement therapeutic approaches due to their unlimited self-renewal potential and ability to differentiate into different somatic cells. A significant progress has been made toward generating iPSC lines that are free of integrating viral vectors, development of xeno-free culture conditions, and differentiation of pluripotent stem cells (PSCs) into functional somatic cell lineages. Since donor-specific iPSC lines are genetically identical to the individual, they are expected to be immunologically matched and these iPSC lines and their cellular derivatives are not expected to be immunologically rejected. However, studies in mouse models, utilizing rejection of teratomas as a model, have claimed that syngenic iPSC lines, especially the iPSC lines derived with integrating viral vectors, could be inherently immunogenic. This manuscript reviews current understanding of inherent immunogenicity of PSC lines, especially that of the human iPSC lines and their cellular derivatives, and strategies to overcome it.
供体特异性诱导多能干细胞(iPSC)因其无限的自我更新潜力和分化为不同体细胞的能力,为个性化细胞替代治疗方法提供了机会。在生成无整合病毒载体的iPSC系、无血清培养条件的开发以及多能干细胞(PSC)向功能性体细胞谱系的分化方面已经取得了重大进展。由于供体特异性iPSC系在基因上与个体相同,预计它们在免疫上是匹配的,并且这些iPSC系及其细胞衍生物预计不会被免疫排斥。然而,在小鼠模型中利用畸胎瘤排斥作为模型的研究声称,同基因iPSC系,尤其是通过整合病毒载体衍生的iPSC系,可能具有内在免疫原性。本文综述了目前对PSC系,特别是人iPSC系及其细胞衍生物的内在免疫原性的理解,以及克服它的策略。